Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

R&D

Gliomatherapy. Inmunotherapy for high grade brain tumors with a monoclonal antibody

The overall objective of this project is to determine the therapeutic potential of the monoclonal antibody Nilo 1 for the treatment of human high-grade brain tumors, either as monotherapy or in combination with other genotoxic agents.

Nile 1 monoclonal antibody has been generated to against surface antigens of mouse neurosphere cells, and recognizes mouse neural stem cells (type B astrocytes), both in physiological and pathological conditions. Moreover, recent experiments have shown that Nilo1 recognizes a subpopulation of cells in human adult malignant gliomas, being capable of in vitro inhibiting the proliferation of neurospheres.


In order to determine their therapeutic potential in human high-grade brain tumors, its use in the diagnosis of human brain tumors will be validated, the inhibition potential will be tested in human brain tumorespheres and its therapeutic effect will be assessed on human tumor xenografts in mice.

Partners: Consortium between Centro de Investigaciones Biológicas del Consejo Superior de Investigaciones Científicas (CIB-CSIC), Fundación Instituto Madrileño de Estudios Avanzados en nanociencia (IMDEA nanociencia)

Funds: Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (RETOS)

ID: RTC-2015-3846-1

2015-2018